Observational studyImmunologic research2017

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.

Maurizio Benucci et al.PubMed ↗Publisher ↗

No numbers read from the abstract.